AstraZeneca (AZN) stock in focus as its antibody drug Imfinzi gains EU panel support for treating muscle-invasive bladder ...

Ocugen ( NASDAQ: OCGN) disclosed on Tuesday that its gene therapy candidate, OCU410ST, has been granted rare pediatric ...

Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a pioneering biotechnology leader in gene therapies for blindness ...

OCU410ST has received Rare Pediatric Disease Designation for ABCA4-associated retinopathies, potentially allowing Ocugen to ...

BeiGene's Tevimbra gets a highly sought after recommendation.

Eli Lilly is expanding its efforts to advance next-generation pain medications. | Eli Lilly is expanding its efforts to ...

BeiGene (NASDAQ:ONC) (OTCPK:BEIGF) announced that an advisory committee of the European Medicines Agency (EMA), endorsed its ...

A TikTok post for the "McMigraine" remedy -- Coca-Cola and a large order of fries -- caused some people to rush to McDonald's for headache relief, but this combination is not a cure or an effective ...

Discover the key biotech trends moving the industry forward in Europe at a time when there lies uncertainty in global ...

Ocugen's drug to treat retina diseases received a rare pediatric disease designation from U.S. regulators. The biotechnology said Tuesday that the Food and Drug Administration granted the designation ...

EU regulators have recommended AstraZeneca’s Imfinzi for approval in the treatment muscle-invasive bladder cancer (MIBC).

AstraZeneca AZN announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) rendered ...